Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 3/20 | 0.52 |
| ▸ | CYP11B1 | P15538 | 2/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.50 |
| ▸ | XDH | P47989 | 2/20 | 0.48 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.48 |
| ▸ | GSK3B | P49841 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.41 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.41 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.41 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.41 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4191925 | 0.86 | XDH (0.61) | ALPLCYP11B1CYP11B2XDHSLC22A12 | |
| SCHEMBL2139463 | 0.84 | CYP11B2 (0.62) | ALPLCYP11B1CYP11B2XDHCYP1A2 | |
| SCHEMBL4196481 | 0.82 | ALPL (0.47) | ALPLXDHSLC22A12GSK3BMEN1 | |
| SCHEMBL4195748 | 0.82 | KCNH2 (0.52) | ALPLCYP11B1CYP11B2XDHSLC22A12 | |
| SCHEMBL4187553 | 0.81 | LRRK2 (0.43) | ALPLCYP11B2XDHSLC22A12ABCG2 | |
| SCHEMBL4196858 | 0.77 | XDH (0.50) | ALPLCYP11B1CYP11B2XDHSLC22A12 | |
| SCHEMBL4201191 | 0.77 | ALPL (0.41) | ALPLGSK3BMEN1KMT2ACYP2C9 | |
| SCHEMBL4199347 | 0.76 | TDP2 (0.58) | ALPLCYP3A4CYP2C9ABCG2SCN9A | |
| SCHEMBL5450744 | 0.76 | GAA (0.68) | GSK3BMEN1KMT2AACP1KDM4E | |
| SCHEMBL4187483 | 0.75 | ALPL (0.49) | ALPLXDHSLC22A12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090196912-A1 | Pyridinylamines | GPC BOTECH AG (DE) | 2009-08-06 | — | — | US | claimed |
| EP-1789393-A2 | PYRIDINYLAMINES | GPC Biotech AG (DE) | 2007-05-30 | — | — | EP | claimed |
| WO-2006010637-A2 | PYRIDINYLAMINES | GPC BIOTECH AG (DE) | 2006-02-02 | — | — | WO | claimed |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2020-07-02 | — | — | US | disclosed |
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | BROWN DENNIS M (US) | 2019-08-20 | — | — | US | disclosed |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | BROWN DENNIS M (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10383847-B2 | Compositions and methods to improve the therapeutic benefit of indirubin and analogs thereof, including meisoindigo | NEK9, NEK7, NEK3 | ALPL 1226/4885CYP11B1 64/4885CYP11B2 149/4885 |
| US-20200206188-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | ALPL 1226/4885CYP11B1 64/4885CYP11B2 149/4885 |
| US-20160243077-A1 | COMPOSITIONS AND METHODS TO IMPROVE THE THERAPEUTIC BENEFIT OF INDIRUBIN AND ANALOGS THEREOF, INCLUDING MEISOINDIGO | NEK9, NEK7, NEK3 | ALPL 1226/4885CYP11B1 64/4885CYP11B2 149/4885 |
| US-20090196912-A1 | Pyridinylamines | PRNP, PLPBP, SNCA | ALPL 2140/4885CYP11B1 348/4885CYP11B2 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.